Usporedite metode

	Indeks kvalitete života u dermatologiji (Dermatology Life Quality Index)	EORTC QLQ-C30	Upitnik o utjecaju fibromialgije (Fibromyalgia Impact Questionnaire)
Područje	Zdravstveni ishodi	Zdravstveni ishodi	Zdravstveni ishodi
Obitelj	Process / pipeline	Process / pipeline	Process / pipeline
Godina nastanka	1994	1993	1991
Tvorac	Andrew Y. Finlay and Gul K. Khan	Nico Aaronson et al.	Cynthia S. Burckhardt et al.
Vrsta	Self-report quality of life questionnaire	Self-report quality of life questionnaire	Self-report symptom and functional impairment questionnaire
Temeljni izvor	Finlay, A. Y., & Khan, G. K. (1994). Dermatology Life Quality Index (DLQI): A simple practical measure for routine clinical use. Clinical and Experimental Dermatology, 19(3), 210-216.	Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., ... & Takeda, F. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.	Burckhardt, C. S., Clark, S. R., & Bennett, R. M. (1991). The Fibromyalgia Impact Questionnaire: Development and validation. The Journal of Rheumatic Diseases, 18(5), 728-735.
Drugi nazivi	DLQI, Finlay Index, Dermatology Quality of Life	QLQ-C30, EORTC QLQ-C30, Cancer Quality of Life Scale	FIQ, Fibromyalgia Impact, Fibromyalgia Questionnaire
Srodne	3	5	4
Sažetak	The DLQI is the primary patient-centered outcome measure in dermatology research and clinical practice. Developed by Andrew Finlay and Gul Khan in 1994, this 10-item self-report questionnaire quantifies the impact of skin disease on patients' daily functioning, emotional well-being, social relationships, and work capacity. It is simple, rapid, and applicable to virtually all dermatological conditions, making it the gold standard for assessing quality of life in dermatology.	The EORTC QLQ-C30 is the most widely used international instrument for assessing quality of life in cancer patients. Developed by the European Organisation for Research and Treatment of Cancer in 1993, it measures physical, emotional, cognitive, and social functioning alongside cancer-specific symptoms and financial impact, making it the standard outcome measure in oncology clinical trials and patient care.	The FIQ is the most widely used patient-reported outcome measure for fibromyalgia disease burden. Developed by Cynthia Burckhardt and colleagues in 1991, this 10-item questionnaire quantifies how fibromyalgia affects physical function, work capacity, depression, anxiety, sleep, pain, and fatigue. The revised version (FIQR, 21 items) offers enhanced psychometric properties and is the current standard in fibromyalgia clinical trials and practice.